Oral Wegovy approved. The $100 billion weight loss drug market sees the start of the “pill vs. injection” showdown.

The FDA has just approved the first oral GLP-1 drug for weight management.

Clinical data shows it can reduce weight by about 16%, which is essentially comparable to the effects of injections. As someone who has consistently followed the pharmaceutical sector, I believe we underestimate how many people have needle phobia or simply prefer the convenience of taking a pill daily.

Novo Nordisk says their product could launch as early as January, while Lilly's oral drug approval will take several more months.

How might this impact Lilly's stock price?

I currently hold Lilly shares and am closely monitoring Lilly's response.